Log in

CorMedix Stock Price, Forecast & Analysis (NYSEAMERICAN:CRMD)

$5.56
+0.44 (+8.59 %)
(As of 11/18/2019 03:44 AM ET)
Today's Range
$5.22
Now: $5.56
$5.70
50-Day Range N/A
52-Week Range
$4.20
Now: $5.56
$13.70
Volume255,727 shs
Average Volume424,898 shs
Market Capitalization$142.62 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:CRMD
Previous SymbolNYSEMKT:CRMD
CUSIPN/A
Phone+1-908-5179500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees22
Market Cap$142.62 million
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable

Receive CRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter.


CorMedix (NYSEAMERICAN:CRMD) Frequently Asked Questions

What is CorMedix's stock symbol?

CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."

When did CorMedix's stock split? How did CorMedix's stock split work?

CorMedix's stock reverse split on Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 25th 2019. An investor that had 100 shares of CorMedix stock prior to the reverse split would have 20 shares after the split.

How were CorMedix's earnings last quarter?

CorMedix Inc. (NYSEAMERICAN:CRMD) announced its earnings results on Thursday, November, 14th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.03. The biotechnology company earned $0.06 million during the quarter, compared to the consensus estimate of $0.19 million. View CorMedix's Earnings History.

When is CorMedix's next earnings date?

CorMedix is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for CorMedix.

What price target have analysts set for CRMD?

2 brokerages have issued 1-year price objectives for CorMedix's stock. Their forecasts range from $14.00 to $30.00. On average, they expect CorMedix's stock price to reach $22.00 in the next year. This suggests a possible upside of 295.7% from the stock's current price. View Analyst Price Targets for CorMedix.

What is the consensus analysts' recommendation for CorMedix?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CorMedix.

Has CorMedix been receiving favorable news coverage?

Media stories about CRMD stock have trended very negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. CorMedix earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View News Stories for CorMedix.

Are investors shorting CorMedix?

CorMedix saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 3,900,000 shares, an increase of 26.2% from the September 15th total of 3,090,000 shares. Based on an average daily volume of 268,400 shares, the days-to-cover ratio is presently 14.5 days. Currently, 16.9% of the company's shares are sold short. View CorMedix's Current Options Chain.

Who are some of CorMedix's key competitors?

What other stocks do shareholders of CorMedix own?

Who are CorMedix's key executives?

CorMedix's management team includes the folowing people:
  • Mr. Khoso Baluch, CEO & Director (Age 61)
  • Mr. Robert W. Cook, Chief Financial Officer (Age 63)
  • Mr. John L. Armstrong Jr., Head of HR & Exec. VP of Technical Operations (Age 75)
  • Ms. Elizabeth Masson, Exec. VP & Head of Clinical Operations (Age 40)
  • Dr. Phoebe Mounts, Exec. VP & Gen. Counsel

Who are CorMedix's major shareholders?

CorMedix's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Steward Partners Investment Advisory LLC (0.23%), Planning Directions Inc. (0.19%), Wealthstreet Investment Advisors LLC (0.07%), Essex Financial Services Inc. (0.04%) and Tower Research Capital LLC TRC (0.02%). Company insiders that own CorMedix stock include Hudson Executive Capital Lp, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Robert W Cook and Steven W Lefkowitz. View Institutional Ownership Trends for CorMedix.

Which institutional investors are selling CorMedix stock?

CRMD stock was sold by a variety of institutional investors in the last quarter, including Steward Partners Investment Advisory LLC. View Insider Buying and Selling for CorMedix.

Which institutional investors are buying CorMedix stock?

CRMD stock was bought by a variety of institutional investors in the last quarter, including Planning Directions Inc., Essex Financial Services Inc., Tower Research Capital LLC TRC and Wealthstreet Investment Advisors LLC. Company insiders that have bought CorMedix stock in the last two years include Hudson Executive Capital Lp, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Robert W Cook and Steven W Lefkowitz. View Insider Buying and Selling for CorMedix.

How do I buy shares of CorMedix?

Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is CorMedix's stock price today?

One share of CRMD stock can currently be purchased for approximately $5.56.

How big of a company is CorMedix?

CorMedix has a market capitalization of $142.62 million. CorMedix employs 22 workers across the globe.View Additional Information About CorMedix.

What is CorMedix's official website?

The official website for CorMedix is http://www.cormedix.com/.

How can I contact CorMedix?

CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at +1-908-5179500.


MarketBeat Community Rating for CorMedix (NYSEAMERICAN CRMD)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  266 (Vote Outperform)
Underperform Votes:  262 (Vote Underperform)
Total Votes:  528
MarketBeat's community ratings are surveys of what our community members think about CorMedix and other stocks. Vote "Outperform" if you believe CRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel